Medicinova has announced positive interim safety data from its Phase II trial randomized, double-blind, placebo-controlled of MN-166 in ALS (see Aug 2014 news story). MN-166 (ibudilast) is a first in-class, orally bioavailable small molecule phosphodiesterase-4 and -10 inhibitor, as well as and a macrophage migration inhibitor factor inhibitor, which exerts both anti-inflammatory and neuroprotective effects. The interim review of data from the first 21 subjects enrolled in the clinical trial found no increase in adverse events in treated subjects as compared to placebo-treated patients. Based on these data, the trial will continue to complete full enrollment and trial rollout. Interestingly, the trial leveraged the CDC’s National ALS Registry, and all registered patients who met the inclusion criteria were notified of the trial.
Click here to read more.